08.05.10 - SIGA Technologies Reports Financial Results For The Second Quarter And First Half Of 2010
08.02.10 - SIGA To Discuss Second Quarter Results Of Operations On August 5, 2010
06.23.10 - SIGA Completes Fourth Successful Human Safety Clinical Trial
06.21.10 - Andy Stern Joins SIGA's Board of Directors
05.12.10 - SIGA CEO Dr. Eric Rose Addresses Congressional Appropriations Subcommittee on Behalf of The Alliance For Biosecurity
05.04.10 - Correction: SIGA Technologies Reports Operating Results For The First Quarter of 2010
05.04.10 - SIGA Technologies Reports Operating Results For The First Quarter of 2010
04.27.10 - SIGA to Discuss First Quarter Results of Operations on May 4th, 2010
03.10.10 - SIGA Technologies Reports Financial Results For The Fourth Quarter and Full Year of 2009
03.05.10 - SIGA to Discuss Fourth Quarter and Year-end 2009 Results of Operations on March 10, 2010
03.01.10 - SIGA to Participate at RBC Capital Makets and Cowen & Company Healthcare Conferences
02.25.10 - SIGA Awarded $2.8 Million DoD Contract With Additional Options For The Development of a Broad Spectrum Antiviral Drug
01.19.10 - Israel Taps SIGA Technologies' ST-246® To Combat Smallpox In Simulated Bioterror Attack
12.14.09 - SIGA Technologies, Inc. Announces Close Of $20 Million Common Stock Offering
12.11.09 - SIGA To Hold Conference Call On Monday, December 14, 2009 At 8:30 A.M. EDT
12.10.09 - SIGA Technologies, Inc. Raises $20.0 Million In A Common Stock Offering
11.09.09 - SIGA Technologies Reports Operating Results For The Third Quarter Of 2009
11.05.09 - SIGA Presents Update on ST-246® Development To The World Health Organization
11.03.09 - SIGA Technologies To Discuss Third Quarter 2009 Results of Operation On November 9 2009
10.30.09 - SIGA Technologies Files $100 Million Shelf Registration
09.29.09 - $1.6 Million NIH Cooperative Agreement Supports SIGA Broad Spectrum Antiviral Research
09.15.09 - ST-246® Used To Treat Complications From Exposure To Recombinant Vaccinia Virus
09.03.09 - SIGA Technologies, Inc. Approved For Nasdaq Global Market Listing
09.02.09 - SIGA Technologies Receives a $3 Million Research Grant From The National Institutes of Health
08.06.09 - SIGA Technologies Reports Operating Results For the Second Quarter of 2009
08.03.09 - SIGA Technologies Reschedules Quarterly Update Call to 10:30 AM EDT on August 6, 2009
07.27.08 - SIGA Technologies to Announce Second Quarter 2009 Results of Operations On August 6, 2009
06.29.09 - SIGA Reaches Next Stage in BARDA's RFP Bidding Process
06.26.09 - SIGA Technologies, Inc. to be Added to the Russell 3000® and Russel Global® Indices
06.15.09 - SIGA Completes Nonclinical Toxicology Studies Supporting Safety in Humans For ST-246®
06.09.09 - SIGA Proposal to Fund Work on Broad Spectrum Antiviral Selected For Award by Department of Defense
06.05.09 - SIGA Technologies, Inc. to Present at The 2009 Noble Financial Fifth Annual Equity Conference
05.14.09 - SIGA Technologies Submits Response to Barda RFP;
Reports Operating Results For The First Quarter of 2009
05.08.09 - SIGA Technologies to Announce First Quarter 2009 Results of Operations on May 14th, 2009
03.30.09 - SIGA Produces FDA Registration Batches of ST-246® Drug Product
03.12.09 - SIGA to Respond to BARDA's Request For Proposal Seeking 1.7 Million Courses of Smallpox Antiviral
03.09.09 - SIGA Technologies to Discuss Year-end 2008 Results of Operations on March 12, 2009
02.24.09 - ST-246® in Combination With The Smallpox Vaccine ACAM2000(tm) Confers Protective Immunity in Primates
02.11.09 - BARDA Issues a Presolicitation for Acquisition of a Smallpox Antiviral
01.13.09 - SIGA Clarifies European Regulatory Path for Lead Smallpox Antiviral ST-246
12.17.08 - SIGA Completes Manufacture of ST-246 Registration Batches
12.02.08 - Siga Technologies Completes Human Pharmacokinetic Bridging Study Validating Commercial Formulation
11.12.08 - SIGA To Present ST-246 To The World Health Organization
11.10.08 - SIGA Technologies Reports Operating Results For The Third Quater Of 2008
11.06.08 - SIGA Technologies To Present At The Rodman & Renshaw Annual Global Investment Confrence
11.03.08 - SIGA Applauds Efforts To Promote Private Sector Participation In Smallpox Biodefense
10.31.08 - SIGA Technologies To Announce Third Quarter 2008 Results of Operations on November 10, 2008
10.23.08 - SIGA Technologies Named To Deloitte Tri-State Area Technology Fast 50
10.15.08 - SIGA Technologies' ST-246 Named "Molocule Of The Month" By Prous Science
10.14.08 - SIGA To Present At The Homeland Security Investor Confrence
09.25.08 - SIGA Technologies To Participate in Committee Meekting For The Institute Of Medicine
09.18.08 - SIGA Technologies Receives Additional $20 Million From NIH For ST-246 Anitviral Therapeutic Development
09.18.08 - SIGA Technologies To Attend The HHS Public Health Emergency Medical Countermeasures Enterprise Stakeholders Workshop 2008 & BARDA Industry Day
09.15.08 - NIH Funds SIGA Lassa Antiviral Program
09.12.08 - NIH Funds SIGA Dengue Antiviral Program
09.03.08 - SIGA Technologies Awarded $55 Million by Federal Government to Develop Broader Applications for its Lead Drug Candidate ST-246
08.12.08 - SIGA Technologies Reports Operating Results For The Second Quarter of 2008
08.05.08 - SIGA Technologies to Announce Second Quarter 2008 Results of Operations on August 12, 2008
06.23.08 - SIGA Receives $8 Million In Financing Support From MacAndrews & Forbes
05.21.08 - SIGA Advances Dengue Antiviral Program
05.12.08 - SIGA Technologies Reports Operating Results For The First Quarter Of 2008
05.07.08 - SIGA Adds Vice President Of Clinical And Regulatory Affairs To Management Team
05.06.08 - SIGA Technologies To Announce First Quarter 2008 Results Of Operations On May 12, 2008
04.29.08 - SIGA Begins Negotiations With Government Agency For Additional Funding To Accelerate ST-246 Commercial Scale Manufacturing
04.18.08 - Dr. Dennis E. Hruby, Chief Science Officer of SIGA Technologies, to Present CDC Distinguished Lecture on Smallpox Antiviral Drug ST-246
04.15.08 - SIGA Advances ST-246 Smallpox Antiviral Development in Europe
04.04.08 - SIGA Initiates Manufacture of ST-246 NDA Registration Batches
03.27.08 - SIGA Successfully Completes ST-246 Multiple Ascending Dose Human Clinical Trial
03.24.08 - SIGA Files Application Supporting Emergency Use Approval for ST-246
03.17.08 - SIGA Technologies Retains KCSA Strategic Communications as Investor Relations Counsel
02.29.08 - SIGA to Present at Susquehanna's Significant Options In Healthcare Conference
01.07.08 - SIGA to Present at The 26th Annual JPMorgan Healthcare Conference
12.20.07 - SIGA CEO, Dr. Eric Rose, Selected To Serve As Member of National Biodefense Science Board
12.06.07 - SIGA Completes 21 Day Multi-dose Human Clinical Safety And Dose-ranging Trial Of Its Lead Smallpox Drug ST-246
11.26.07 - SIGA Cheif Scientific Officer, Dennis Hruby To Present ST-246 Progress And Human Clinical Safety Study Data To The World Health Organization (WHO)
11.08.07 - SIGA Technologies to Announce Third Quarter 2007 Results Of Operations
09.26.07 - ST-246 Completely Prevents Mortality in Symptomatic Orthopox Virus Infected Primates
06.19.07 - SIGA Technologies To Join The Russell Microcap Index
05.15.07 - SIGA Passes First Hurdle With Lassa Fever Antivirial ST-193
04.23.07 - SIGA Technologies To Announce First Quarter 2007 Results of Operations
03.19.07 - SIGA’s Smallpox Drug Candidate Administered To Critically Ill Human Patient
02.13.07 - SIGA Begins Second Human Safety Trial Of It’s Lead Smallpox Drug
01.31.07 - SIGA Appoints Dr. Eric Rose Chairman Of The Board, Will Become CEO On March 1, 2007
12.20.06 - FDA Approves Orphan Drug Designation For SIGA’s Smallpox Drug, SIGA-246
12.19.06 - Infectious Diseases Specialist, Scott M. Hammer, M.D. Joins SIGA’s Board Of Directors
11.16.06 - SIGA Technologies Presents Its Smallpox Drug (SIGA-246) To The World Health Organization (WHO)
11.10.06 - SIGA Announces 2.3 Million In New Contracts With The U.S. Air Force
11.09.06 - SIGA Passes Another Milestone With Smallpox Drug SIGA-246
10.19.06 - SIGA Announces $9.0 Million Private Placement
10.18.06 - SIGA Announces Smallpox Treatment Breakthrough - SIGA Drug Completely Prevents Smallpox Disease In Preliminary Primate Trial
10.05.06 - SIGA Receives $16.5 Million From The NIH To Advance Development Of Its Smallpox Drug Candidate, SIGA-246
09.12.06 - SIGA Announces $6.0 Million Grant To Support Its Lassa Fever Antiviral Program.
08.02.06 - SIGA Announces $4.8 Million Grant For SIGA-246, It’s Smallpox Drug Candidate.
07.13.06 - SIGA Announces Successful Completion Of Its Smallpox Drug Candidate’s Initial Human Safety Trial.
Click here to print this page
